Cingulate Inc
CING7.700USD
+1.210+18.64%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
46.03M시가총액
손실P/E TTM
자세한 내용은 Cingulate Inc 회사
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Inc 정보
종목 코드 CING
회사 이름Cingulate Inc
상장일Oct 07, 2021
CEOCallahan (Jennifer L)
직원 수13
유형Ordinary Share
회계 연도 종료Oct 07
주소1901 W. 47Th Place
도시KANSAS CITY
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호66205
전화19139422300
웹사이트https://www.cingulate.com/
종목 코드 CING
상장일Oct 07, 2021
CEOCallahan (Jennifer L)
Cingulate Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Fri, Feb 6
마지막 업데이트: Fri, Feb 6
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
2.06%
Werth Family Investment Associates LLC
1.34%
Kestra Advisory Services, LLC
1.28%
Geode Capital Management, L.L.C.
0.58%
UBS Financial Services, Inc.
0.38%
기타
94.37%
주주
주주
비율
The Vanguard Group, Inc.
2.06%
Werth Family Investment Associates LLC
1.34%
Kestra Advisory Services, LLC
1.28%
Geode Capital Management, L.L.C.
0.58%
UBS Financial Services, Inc.
0.38%
기타
94.37%
주주 유형
주주
비율
Investment Advisor
4.45%
Corporation
1.38%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.25%
기타
93.23%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
33
295.34K
5.70%
--
2025Q3
44
295.34K
6.89%
+113.00
2025Q2
41
295.23K
5.36%
+158.62K
2025Q1
38
136.60K
4.92%
-48.84K
2024Q4
38
91.23K
3.95%
+40.70K
2024Q3
38
50.54K
3.01%
-30.23K
2024Q2
36
80.24K
1.97%
+46.92K
2024Q1
36
33.32K
1.85%
+25.60K
2023Q4
33
318.00
10.05%
-5.36K
2023Q3
30
5.68K
6.07%
+3.89K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
73.80K
1.03%
+38.42K
+108.60%
Sep 30, 2025
Werth Family Investment Associates LLC
97.99K
1.36%
--
--
Aug 01, 2025
Kestra Advisory Services, LLC
94.02K
1.31%
+94.02K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
42.41K
0.59%
+10.25K
+31.88%
Sep 30, 2025
UBS Financial Services, Inc.
1.30K
0.02%
-11.35K
-89.74%
Sep 30, 2025
LPL Financial LLC
20.25K
0.28%
+8.07K
+66.32%
Sep 30, 2025
Virtu Americas LLC
10.77K
0.15%
-2.58K
-19.32%
Sep 30, 2025
Quantum Private Wealth, LLC
24.00K
0.33%
+14.00K
+140.00%
Sep 30, 2025
Northern Trust Investments, Inc.
8.00K
0.11%
+8.00K
--
Sep 30, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
날짜
배당락일
유형
비율
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
